MarketPulse

oral medications

2 articles
BenzingaBenzinga··Vandana Singh

Novo Nordisk Widens Obesity Drug Gap as Lilly's Pill Launch Stumbles

Eli Lilly's obesity pill logged 1,390 first-week prescriptions versus Novo Nordisk's 3,071 in four days, as $NVO maintains commanding 113,354 weekly Wegovy prescriptions.
LLYNVOmarket sharepharmaceutical competition
The Motley FoolThe Motley Fool··Rich Smith

Novo Nordisk Stock Pullback Creates Entry Point for Long-Term GLP-1 Investors

Novo Nordisk stock down 67% offers entry point for long-term investors. Strong GLP-1 market position, attractive valuation metrics, and growth potential despite upcoming competition.
LLYNVOstock valuationdividend stocks